Showing results (11-20 of 113) with videos related to
Sort By:
Pageof 12
Best Practice & Research. Clinical Haematology|November 10, 2016
Future therapeutic options for patients with Waldenström macroglobulinemiaJorge J Castillo, Zachary R Hunter, Guang Yang, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 7, 2018
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid CancerTilly Varughese, Ying Taur, Nina Cohen, et al.Investigational New Drugs|February 18, 2018
Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I studyAnastasios Stathis, Ian W Flinn, Sumit Madan, et al.Leukemia & Lymphoma|May 21, 2021
Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trialsM Lia Palomba, Monika Parisi Jun, James Lymp, et al.Open Forum Infectious Diseases|November 18, 2015
West Nile Virus Central Nervous System Infection in Patients Treated With Rituximab: Implications for Diagnosis and Prognosis, With a Review of LiteratureSejal Morjaria, Esther Arguello, Ying Taur, et al.Blood Cancer Journal|August 21, 2021
Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trialFranck Morschhauser, Nilanjan Ghosh, Izidore S Lossos, et al.Cell Reports|July 25, 2019
Constitutive Activation of the B Cell Receptor Underlies Dysfunctional Signaling in Chronic Lymphocytic LeukemiaCarly G K Ziegler, Joel Kim, Kelly Piersanti, et al.Clinical Lymphoma, Myeloma & Leukemia|January 15, 2022
Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b StudyM Lia Palomba, Brian G Till, Steven I Park, et al.Journal for Immunotherapy of Cancer|February 17, 2022
CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experienceM Lia Palomba, David Qualls, Sebastien Monette, et al.British Journal of Haematology|March 6, 2020
Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapyBrandon S Imber, Michel Sadelain, Carl DeSelm, et al.Pageof 12